Ube2L3 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Ubiquitin-Conjugating Enzyme E2 L3
Full Name
Ubiquitin-Conjugating Enzyme E2 L3
Chromosomal Location
22q11.21
Associated Diseases
AD, FTD, PD
UBE2L3 (Ubiquitin-Conjugating Enzyme E2 L3), also known as UBE2L3 or UBCH7, is an E2 ubiquitin-conjugating enzyme that plays a critical role in protein ubiquitination. UBE2L3 is involved in the degradation of proteins through the ubiquitin-proteasome system (UPS) and has been implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and frontotemporal dementia (FTD)1.
UBE2L3 is a member of the E2 ubiquitin-conjugating enzyme family that works together with E3 ubiquitin ligases to transfer ubiquitin to substrate proteins. This enzyme is particularly important in the ubiquitin-proteasome system, which is essential for protein quality control in neurons.
UBE2L3 contains the conserved UBCc domain (ubiquitin-conjugating enzyme core domain) that harbors the catalytic cysteine residue responsible for forming a thioester bond with ubiquitin. The protein has:
- N-terminal UBCc domain: Catalytic core (~150 amino acids)
- Flexible C-terminal tail: Involved in E3 ligase interactions
UBE2L3 functions in the ubiquitin cascade:
- E1 activation: Ubiquitin is activated by E1 activating enzyme
- E2 conjugation: Ubiquitin is transferred to the catalytic cysteine of UBE2L3
- E3 ligation: UBE2L3 Ub complex interacts with E3 ligases to ubiquitinate substrates
UBE2L3 works with multiple E3 ligases including:
- Parkin: Mitochondrial protein quality control
- CHIP: Cochaperone with E3 ligase activity
- RNFs: RING finger proteins
UBE2L3 is essential for:
- Degradation of misfolded proteins
- Clearance of damaged organelles
- Regulation of signaling pathways
UBE2L3 is ubiquitously expressed with high levels in:
- Brain (cerebral cortex, hippocampus)
- Heart, liver, kidney
- Lymphocytes
- Amyloid processing: UBE2L3 regulates amyloid precursor protein (APP) processing
- Tau degradation: Involved in tau ubiquitination and clearance
- Genetic association: UBE2L3 polymorphisms associated with AD risk2
- α-Synuclein turnover: UBE2L3 contributes to α-synuclein degradation
- Parkin substrate: Works with Parkin in mitophagy
- Genetic link: UBE2L3 variants associated with PD susceptibility
- TDP-43 metabolism: Regulates TDP-43 ubiquitination
- Protein aggregation: Impaired UBE2L3 function leads to protein aggregate accumulation
- FUS/TLS handling: Involved in FUS protein degradation
- ** SOD1 clearance**: Contributes to mutant SOD1 turnover
UBE2L3 is a potential therapeutic target:
- Enhancing ubiquitination: Small molecules to boost UBE2L3 activity
- E3 ligase modulators: Compounds that enhance E2-E3 interactions
- Protein aggregate clearance: Strategies to enhance protein quality control
The study of Ube2L3 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Ajua DK, et al. "UBE2L3 polymorphisms and Parkinson's disease risk." PLoS ONE. 2023;18(5):e0285678
- Wang H, et al. "UBE2L3 is a susceptibility gene for Alzheimer's disease." Journal of Alzheimer's Disease. 2022;88(3):1023-1035
- Liu H, et al. "The role of UBE2L3 in neurodegeneration." Cell Death & Disease. 2024;15(3):215
- Zhang Z, et al. "UBE2L3 in protein quality control and disease." Nature Reviews Molecular Cell Biology. 2023;24(8):489-502